Clinical Trial Update: Lab Study of MQX-503 in Treatment of Raynaud's [Phase 2, Phase 3]

View source ↗

Summary

MQX-503 for Raynaud's phenomenon completed Phase 2 and Phase 3 trials; the update does not provide efficacy results in this brief.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Raynaud Phenomenon
• Raynaud Phenomenon Secondary to Autoimmune Disease
• Raynaud Phenomenon Secondary to Scleroderma

Drugs mentioned

• MQX-503

Snippet

Sponsor: MediQuest Therapeutics | Conditions: Raynaud Disease, Raynaud Disease Secondary to Scleroderma | Phase 2, Phase 3 | Status: COMPLETED